{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T04:50:53Z","timestamp":1755838253128,"version":"3.37.3"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T00:00:00Z","timestamp":1329782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1038\/nrneph.2012.14","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T10:30:24Z","timestamp":1329820224000},"page":"234-243","source":"Crossref","is-referenced-by-count":36,"title":["Novel approaches for reducing free light chains in patients with myeloma kidney"],"prefix":"10.1038","volume":"8","author":[{"name":"on behalf of the International Kidney and Monoclonal Gammopathy Research Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin A.","family":"Hutchison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cockwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Drayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Fermand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Winearls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,21]]},"reference":[{"key":"BFnrneph201214_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516\u20132520 (2008).","journal-title":"Blood"},{"key":"BFnrneph201214_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9, J. et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch. Intern. Med. 158, 1889\u20131893 (1998).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph201214_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21\u201333 (2003).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrneph201214_CR4","first-page":"78","volume":"9","author":"CC Chow","year":"2003","unstructured":"Chow, C. C. et al. Renal impairment in patients with multiple myeloma. Hong Kong Med. J. 9, 78\u201382 (2003).","journal-title":"Hong Kong Med. J."},{"key":"BFnrneph201214_CR5","first-page":"517","volume":"79","author":"HC Rayner","year":"1991","unstructured":"Rayner, H. C., Haynes, A. P., Thompson, J. R., Russell, N. & Fletcher, J. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q. J. Med. 79, 517\u2013525 (1991).","journal-title":"Q. J. Med."},{"key":"BFnrneph201214_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","volume":"91","author":"R Torra","year":"1995","unstructured":"Torra, R. et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br. J. Haematol. 91, 854\u2013859 (1995).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph201214_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","volume":"65","author":"LM Knudsen","year":"2000","unstructured":"Knudsen, L. M., Hjorth, M. & Hippe, E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur. J. Haematol. 65, 175\u2013181 (2000).","journal-title":"Eur. J. Haematol."},{"key":"BFnrneph201214_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00277-009-0813-8","volume":"89","author":"K Matsue","year":"2010","unstructured":"Matsue, K. et al. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann. Hematol. 89, 291\u2013297 (2010).","journal-title":"Ann. Hematol."},{"key":"BFnrneph201214_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","volume":"9","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos, M. A. et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin. Lymphoma Myeloma 9, 302\u2013306 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"BFnrneph201214_CR10","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","volume":"150","author":"R Alexanian","year":"1990","unstructured":"Alexanian, R., Barlogie, B. & Dixon, D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch. Intern. Med. 150, 1693\u20131695 (1990).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph201214_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrneph.2011.168","volume":"8","author":"CA Hutchison","year":"2012","unstructured":"Hutchison, C. A. et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat. Rev. Nephrol. 8, 43\u201351 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201214_CR12","first-page":"527","volume":"64","author":"PW Sanders","year":"1991","unstructured":"Sanders, P. W., Herrera, G. A., Kirk, K. A., Old, C. W. & Galla, J. H. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab. Invest. 64, 527\u2013537 (1991).","journal-title":"Lab. Invest."},{"key":"BFnrneph201214_CR13","first-page":"324","volume":"13","author":"PW Sanders","year":"1993","unstructured":"Sanders, P. W. & Herrera, G. A. Monoclonal immunoglobulin light chain-related renal diseases. Semin. Nephrol. 13, 324\u2013341 (1993).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph201214_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000096763","volume":"153","author":"GA Herrera","year":"2007","unstructured":"Herrera, G. A. & Sanders, P. W. Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrib. Nephrol. 153, 105\u2013115 (2007).","journal-title":"Contrib. Nephrol."},{"key":"BFnrneph201214_CR15","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJM199106273242603","volume":"324","author":"A Solomon","year":"1991","unstructured":"Solomon, A., Weiss, D. T. & Kattine, A. A. Nephrotoxic potential of Bence Jones proteins. N. Engl. J. Med. 324, 1845\u20131851 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201214_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05045.x","volume":"126","author":"GP Mead","year":"2004","unstructured":"Mead, G. P. et al. Serum free light chains for monitoring multiple myeloma. Br. J. Haematol. 126, 348\u2013354 (2004).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph201214_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3816\/CLM.2007.n.036","volume":"7","author":"S Jagannath","year":"2007","unstructured":"Jagannath, S. Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin. Lymphoma Myeloma 7, 518\u2013523 (2007).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"BFnrneph201214_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/0002-9343(75)90496-9","volume":"58","author":"MJ Stone","year":"1975","unstructured":"Stone, M. J. & Frendel, E. P. The clinical spectrum of light chain myeloma. A study of 35 patients with special reference to the occurrence of amyloidosis. Am. J. Med. 58, 601\u2013619 (1975).","journal-title":"Am. J. Med."},{"key":"BFnrneph201214_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/ndt\/11.3.413","volume":"11","author":"D Chauveau","year":"1996","unstructured":"Chauveau, D. & Choukroun, G. Bence Jones proteinuria and myeloma kidney. Nephrol. Dial. Transplant. 11, 413\u2013415 (1996).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201214_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1172\/JCI115629","volume":"89","author":"PW Sanders","year":"1992","unstructured":"Sanders, P. W. & Booker, B. B. Pathobiology of cast nephropathy from human Bence Jones proteins. J. Clin. Invest. 89, 630\u2013639 (1992).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201214_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/211369a0","volume":"211","author":"BA Askonas","year":"1966","unstructured":"Askonas, B. A. & Williamson, A. R. Biosynthesis of immunoglobulins. Free light chain as an intermediate in the assembly of \u03b3G-molecules. Nature 211, 369\u2013372 (1966).","journal-title":"Nature"},{"key":"BFnrneph201214_CR22","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/ki.1995.421","volume":"48","author":"CG Winearls","year":"1995","unstructured":"Winearls, C. G. Acute myeloma kidney. Kidney Int. 48, 1347\u20131361 (1995).","journal-title":"Kidney Int."},{"key":"BFnrneph201214_CR23","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/ndt\/13.6.1438","volume":"13","author":"JJ Montseny","year":"1998","unstructured":"Montseny, J. J. et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol. Dial. Transplant. 13, 1438\u20131445 (1998).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201214_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3109\/08860229809045152","volume":"20","author":"C Magee","year":"1998","unstructured":"Magee, C., Vella, J. P., Tormey, W. P. & Walshe, J. J. Multiple myeloma and renal failure: one center's experience. Ren. Fail. 20, 597\u2013606 (1998).","journal-title":"Ren. Fail."},{"key":"BFnrneph201214_CR25","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/ki.2008.108","volume":"73","author":"N Leung","year":"2008","unstructured":"Leung, N. et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 73, 1282\u20131288 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph201214_CR26","first-page":"484","volume":"124","author":"PW Sanders","year":"1994","unstructured":"Sanders, P. W. Pathogenesis and treatment of myeloma kidney. J. Lab. Clin. Med. 124, 484\u2013488 (1994).","journal-title":"J. Lab. Clin. Med."},{"key":"BFnrneph201214_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0272-6386(87)80007-0","volume":"10","author":"R Misiani","year":"1987","unstructured":"Misiani, R., Tiraboschi, G., Mingardi, G. & Mecca, G. Management of myeloma kidney: an anti-light-chain approach. Am. J. Kidney Dis. 10, 28\u201333 (1987).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201214_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","volume":"23","author":"A Dispenzieri","year":"2009","unstructured":"Dispenzieri, A. et al. on behalf of the International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23, 215\u2013224 (2009).","journal-title":"Leukemia"},{"key":"BFnrneph201214_CR29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","volume":"47","author":"AR Bradwell","year":"2001","unstructured":"Bradwell, A. R. et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem. 47, 673\u2013680 (2001).","journal-title":"Clin. Chem."},{"key":"BFnrneph201214_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","volume":"143","author":"WF Clark","year":"2005","unstructured":"Clark, W. F. et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann. Intern. Med. 143, 777\u2013784 (2005).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph201214_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1990.00390160111022","volume":"150","author":"WJ Johnson","year":"1990","unstructured":"Johnson, W. J., Kyle, R. A., Pineda, A. A., O'Brien, P. C. & Holley, K. E. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch. Intern. Med. 150, 863\u2013869 (1990).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph201214_CR32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/ki.1988.127","volume":"33","author":"P Zucchelli","year":"1988","unstructured":"Zucchelli, P., Pasquali, S., Cagnoli, L. & Ferrari, G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 33, 1175\u20131180 (1988).","journal-title":"Kidney Int."},{"key":"BFnrneph201214_CR33","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1080\/10428190801930506","volume":"49","author":"M Roussou","year":"2008","unstructured":"Roussou, M. et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk. Lymphoma 49, 890\u2013895 (2008).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrneph201214_CR34","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2215\/CJN.04590908","volume":"4","author":"CA Hutchison","year":"2009","unstructured":"Hutchison, C. A. et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin. J. Am. Soc. Nephrol. 4, 745\u2013754 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201214_CR35","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1681\/ASN.2010080857","volume":"22","author":"CA Hutchison","year":"2011","unstructured":"Hutchison, C. A. et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J. Am. Soc. Nephrol. 22, 1129\u20131136 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201214_CR36","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3324\/haematol.10759","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis, E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92, 546\u2013549 (2007).","journal-title":"Haematologica"},{"key":"BFnrneph201214_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","volume":"73","author":"P Tosi","year":"2004","unstructured":"Tosi, P. et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur. J. Haematol. 73, 98\u2013103 (2004).","journal-title":"Eur. J. Haematol."},{"key":"BFnrneph201214_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bbmt.2010.02.020","volume":"16","author":"P Tosi","year":"2010","unstructured":"Tosi, P. et al. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol. Blood Marrow Transplant. 16, 1115\u20131121 (2010).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrneph201214_CR39","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1211\/0022357022241","volume":"55","author":"T Eriksson","year":"2003","unstructured":"Eriksson, T. et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J. Pharm. Pharmacol. 55, 1701\u20131706 (2003).","journal-title":"J. Pharm. Pharmacol."},{"key":"BFnrneph201214_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1365-2141.2003.04395_2.x","volume":"122","author":"E Harris","year":"2003","unstructured":"Harris, E. et al. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br. J. Haematol. 122, 160\u2013161 (2003).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph201214_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2141.2004.04875.x","volume":"125","author":"F Fakhouri","year":"2004","unstructured":"Fakhouri, F. et al. Thalidomide in patients with multiple myeloma and renal failure. Br. J. Haematol. 125, 96\u201397 (2004).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph201214_CR42","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminhematol.2005.10.005","volume":"42","author":"KC Anderson","year":"2005","unstructured":"Anderson, K. C. & Prince, H. M. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin. Hematol. 42, S1\u2013S2 (2005).","journal-title":"Semin. Hematol."},{"key":"BFnrneph201214_CR43","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1177\/0091270007309563","volume":"47","author":"N Chen","year":"2007","unstructured":"Chen, N. et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol. 47, 1466\u20131475 (2007).","journal-title":"J. Clin. Pharmacol."},{"key":"BFnrneph201214_CR44","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"PG Richardson","year":"2006","unstructured":"Richardson, P. G. et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108, 3458\u20133464 (2006).","journal-title":"Blood"},{"key":"BFnrneph201214_CR45","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber, D. M. et al. for the Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133\u20132142 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201214_CR46","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos, M. et al. for the Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357, 2123\u20132132 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201214_CR47","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1002\/cncr.25139","volume":"116","author":"M Dimopoulos","year":"2010","unstructured":"Dimopoulos, M. et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function. Cancer 116, 3807\u20133814 (2010).","journal-title":"Cancer"},{"key":"BFnrneph201214_CR48","first-page":"3548","volume":"108","author":"DE Reece","year":"2006","unstructured":"Reece, D. E. et al. Use of lenalidomide (Revlimid\u00ae) \u00b1 corticosteroids in relapsed\/refractory multiple myeloma patients with elevated baseline serum creatinine levels [abstract]. Blood (ASH Annual Meeting Abstracts) 108, 3548 (2006).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFnrneph201214_CR49","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-010-1080-4","volume":"90","author":"U Klein","year":"2011","unstructured":"Klein, U. et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann. Hematol. 90, 429\u2013439 (2011).","journal-title":"Ann. Hematol."},{"key":"BFnrneph201214_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.2010.01461.x","volume":"85","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos, M. A. et al. Lenalidomide and dexamethasone for the treatment of refractory\/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur. J. Haematol. 85, 1\u20135 (2010).","journal-title":"Eur. J. Haematol."},{"key":"BFnrneph201214_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1600-0609.2010.01500.x","volume":"85","author":"J de la Rubia","year":"2010","unstructured":"de la Rubia, J. et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur. J. Haematol. 85, 363\u2013365 (2010).","journal-title":"Eur. J. Haematol."},{"key":"BFnrneph201214_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1475-2867-5-18","volume":"5","author":"M Boccadoro","year":"2005","unstructured":"Boccadoro, M., Morgan, G. & Cavenagh, J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5, 18 (2005).","journal-title":"Cancer Cell Int."},{"key":"BFnrneph201214_CR53","first-page":"3477","volume":"110","author":"D Mulkerin","year":"2007","unstructured":"Mulkerin, D. et al. Safety, tolerability and pharmacology of bortezomib in cancer patients with renal failure requiring dialysis: results from a prospective phase 1 study [abstract]. Blood (ASH Annual Meeting Abstracts) 110, 3477 (2007).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFnrneph201214_CR54","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.20888","volume":"103","author":"S Jagannath","year":"2005","unstructured":"Jagannath, S. et al. Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103, 1195\u20131200 (2005).","journal-title":"Cancer"},{"key":"BFnrneph201214_CR55","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/sj.leu.2405087","volume":"22","author":"JF San-Miguel","year":"2008","unstructured":"San-Miguel, J. F. et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 22, 842\u2013849 (2008).","journal-title":"Leukemia"},{"key":"BFnrneph201214_CR56","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","volume":"109","author":"AA Chanan-Khan","year":"2007","unstructured":"Chanan-Khan, A. A. et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal function: a multicenter retrospective study. Blood 109, 2604\u20132606 (2007).","journal-title":"Blood"},{"key":"BFnrneph201214_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1600-0609.2009.01385.x","volume":"84","author":"F Morabito","year":"2010","unstructured":"Morabito, F. et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur. J. Haematol. 84, 223\u2013228 (2010).","journal-title":"Eur. J. Haematol."},{"key":"BFnrneph201214_CR58","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3324\/haematol.11463","volume":"92","author":"H Ludwig","year":"2007","unstructured":"Ludwig, H., Drach, J., Graf, H., Lang, A. & Meran, J. G. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92, 1411\u20131414 (2007).","journal-title":"Haematologica"},{"key":"BFnrneph201214_CR59","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1002\/cncr.25937","volume":"117","author":"J Shah","year":"2011","unstructured":"Shah, J. et al. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed\/refractory myeloma is associated with a longer time to progression. Cancer 117, 3758\u20133762 (2011).","journal-title":"Cancer"},{"key":"BFnrneph201214_CR60","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","volume":"27","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos, M. A. et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of phase III VISTA study. J. Clin. Oncol. 27, 6086\u20136093 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph201214_CR61","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","volume":"28","author":"H Ludwig","year":"2010","unstructured":"Ludwig, H. et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J. Clin. Oncol. 28, 4635\u20134641 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph201214_CR62","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","volume":"34","author":"M Roussou","year":"2010","unstructured":"Roussou, M. et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk. Res. 34, 1395\u20131397 (2010).","journal-title":"Leuk. Res."},{"key":"BFnrneph201214_CR63","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1182\/blood-2010-08-302505","volume":"117","author":"WZ Ying","year":"2011","unstructured":"Ying, W. Z., Wang, P. X., Aaron, K. J., Basnayake, K. & Sanders, P. W. Immunoglobulin light chains activate nuclear factor\u03baB in renal epithelial cells through a Src-dependent mechanism. Blood 117, 1301\u20131307 (2011).","journal-title":"Blood"},{"key":"BFnrneph201214_CR64","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos, M. A. et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol. 28, 4976\u20134984 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph201214_CR65","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1172\/JCI107023","volume":"51","author":"TA Waldmann","year":"1972","unstructured":"Waldmann, T. A., Strober, W. & Mogielnicki, R. P. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J. Clin. Invest. 51, 2162\u20132174 (1972).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph201214_CR66","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0009-8981(67)90036-8","volume":"18","author":"TA Miettinen","year":"1967","unstructured":"Miettinen, T. A. & Kekki, M. Effect of impaired hepatic and renal function on Bence Jones protein catabolism in human subjects. Clin. Chim. Acta 18, 395\u2013407 (1967).","journal-title":"Clin. Chim. Acta"},{"key":"BFnrneph201214_CR67","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2215\/CJN.02290508","volume":"3","author":"CA Hutchison","year":"2008","unstructured":"Hutchison, C. A. et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1684\u20131690 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph201214_CR68","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/14728222.12.6.667","volume":"12","author":"CA Hutchison","year":"2008","unstructured":"Hutchison, C. A. et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease? Expert Opin. Ther. Targets 12, 667\u2013676 (2008).","journal-title":"Expert Opin. Ther. Targets"},{"key":"BFnrneph201214_CR69","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1681\/ASN.2006080821","volume":"18","author":"CA Hutchison","year":"2007","unstructured":"Hutchison, C. A. et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J. Am. Soc. Nephrol. 18, 886\u2013895 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201214_CR70","unstructured":"ISRCTN Register. Myeloma Renal Impairment Trial: adjunctive plasma exchange in patients with newly diagnosed multiple myeloma and acute renal failure [online] , (2009)."},{"key":"BFnrneph201214_CR71","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1537-2995.2006.01143.x","volume":"47","author":"C Cserti","year":"2007","unstructured":"Cserti, C., Haspel, R., Stowell, C. & Dzik, W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 47, 511\u2013514 (2007).","journal-title":"Transfusion"},{"key":"BFnrneph201214_CR72","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1056\/NEJMc1101834","volume":"364","author":"BL Burnette","year":"2011","unstructured":"Burnette, B. L., Leung, N. & Rajkumar, S. V. Renal improvement in myeloma with bortezomib plus plasma exchange. N. Engl. J. Med. 364, 2365\u20132366 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph201214_CR73","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/sj.ki.5000048","volume":"69","author":"RA Ward","year":"2006","unstructured":"Ward, R. A., Greene, T., Hartmann, B. & Samtleben, W. Resistance to intercompartmental mass transfer limits \u03b22-microglobulin removal by post-dilution hemodiafiltration. Kidney Int. 69, 1431\u20131437 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph201214_CR74","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/ndt\/gfr180","volume":"26","author":"A Granger Vall\u00e9e","year":"2011","unstructured":"Granger Vall\u00e9e, A. et al. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal then high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study. Nephrol. Dial. Transplant. 26, 3627\u20133633 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201214_CR75","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.ackd.2011.02.006","volume":"18","author":"B Gondouin","year":"2011","unstructured":"Gondouin, B. & Hutchison, C. A. High cut-off dialysis membranes: current uses and future potential. Adv. Chronic Kidney Dis. 18, 180\u2013187 (2011).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"BFnrneph201214_CR76","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1525-1594.2008.00653.x","volume":"32","author":"CA Hutchison","year":"2008","unstructured":"Hutchison, C. A. et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif. Organs 32, 910\u2013917 (2008).","journal-title":"Artif. Organs"},{"issue":"Suppl. 2","key":"BFnrneph201214_CR77","first-page":"ii9a","volume":"1","author":"CA Hutchison","year":"2008","unstructured":"Hutchison, C. A., Basnayake, K., Cook, M., Bradwell, A. R. & Cockwell, P. Free light chain hemodialysis increases renal recovery rate and improves patient survival in patients with cast nephropathy. Nephrol. Dial. Transplant. 1 (Suppl. 2), ii9a (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201214_CR78","first-page":"106","volume":"1","author":"U Bachmann","year":"2008","unstructured":"Bachmann, U. et al. Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. NDT Plus 1, 106\u2013108 (2008).","journal-title":"NDT Plus"},{"key":"BFnrneph201214_CR79","doi-asserted-by":"publisher","unstructured":"Hutchison, C. A. et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol. Dial. Transplant. http:\/\/dx.doi.org\/10.1093\/ndt\/gfr773 .","DOI":"10.1093\/ndt\/gfr773"},{"key":"BFnrneph201214_CR80","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/ndt\/gfr019","volume":"26","author":"S Harding","year":"2011","unstructured":"Harding, S. et al. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Nephrol. Dial. Transplant. 26, 1438 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201214_CR81","doi-asserted-by":"publisher","unstructured":"Heyne, N. et al. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann. Hematol. http:\/\/dx.doi.org\/10.1007\/s00277-011-1383-0 .","DOI":"10.1007\/s00277-011-1383-0"},{"key":"BFnrneph201214_CR82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1745-6215-9-55","volume":"9","author":"CA Hutchison","year":"2008","unstructured":"Hutchison, C. A. et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised controlled trial. Trials 9, 55 (2008).","journal-title":"Trials"},{"key":"BFnrneph201214_CR83","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online] , (2011)."},{"key":"BFnrneph201214_CR84","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros, A. et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br. J. Haematol. 114, 822\u2013829 (2001).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph201214_CR85","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/sj.thj.6200003","volume":"1","author":"JF San Miguel","year":"2000","unstructured":"San Miguel, J. F. et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol. J. 1, 28\u201336 (2000).","journal-title":"Hematol. J."},{"key":"BFnrneph201214_CR86","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","volume":"33","author":"CK Lee","year":"2004","unstructured":"Lee, C. K. et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 33, 823\u2013828 (2004).","journal-title":"Bone Marrow Transplant."},{"key":"BFnrneph201214_CR87","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","volume":"75","author":"LM Knudsen","year":"2005","unstructured":"Knudsen, L. M., Nielsen, B., Gimsing, P. & Geisler, C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur. J. Haematol. 75, 27\u201333 (2005).","journal-title":"Eur. J. Haematol."},{"key":"BFnrneph201214_CR88","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbmt.2009.03.021","volume":"15","author":"GC Parikh","year":"2009","unstructured":"Parikh, G. C. et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol. Blood Marrow Transplant. 15, 812\u2013816 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrneph201214_CR89","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/pgmj.47.552.635","volume":"47","author":"AA Dawson","year":"1971","unstructured":"Dawson, A. A. & Ogston, D. Factors influencing the prognosis in myelomatosis. Postgrad. Med. J. 47, 635\u2013638 (1971).","journal-title":"Postgrad. Med. J."},{"key":"BFnrneph201214_CR90","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/jcp.25.6.555-d","volume":"25","author":"R Peto","year":"1972","unstructured":"Peto, R. Factors of prognostic significance in myelomatosis. J. Clin. Pathol. 25, 555 (1972).","journal-title":"J. Clin. Pathol."},{"key":"BFnrneph201214_CR91","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1600-0609.2009.01318.x","volume":"83","author":"M Kleber","year":"2009","unstructured":"Kleber, M. et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur. J. Haematol. 83, 519\u2013527 (2009).","journal-title":"Eur. J. Haematol."},{"key":"BFnrneph201214_CR92","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson, B. M. et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002. Medical Research Council Adult Leukaemia Working Party. J. Clin. Oncol. 23, 9219\u20139226 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneph201214_CR93","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2141.2007.06698.x","volume":"138","author":"R Niesvizky","year":"2007","unstructured":"Niesvizky, R. et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br. J. Haematol. 138, 640\u2013643 (2007).","journal-title":"Br. J. Haematol."},{"key":"BFnrneph201214_CR94","first-page":"1477","volume":"110","author":"S Ailawadhi","year":"2007","unstructured":"Ailawadhi, S. et al. Renal dysfunction does not affect clinical response in multiple myeloma (MM) patients treated with bortezomib-based regimens [abstract]. Blood (ASH Annual Meeting Abstracts) 110, 1477 (2007).","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"BFnrneph201214_CR95","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3816\/CLM.2008.n.051","volume":"8","author":"J Blad\u00e9","year":"2008","unstructured":"Blad\u00e9, J. et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin. Lymphoma Myeloma 8, 352\u2013355 (2008).","journal-title":"Clin. Lymphoma Myeloma"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.14","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:38:07Z","timestamp":1684471087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,21]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["BFnrneph201214"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2012.14","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"type":"print","value":"1759-5061"},{"type":"electronic","value":"1759-507X"}],"subject":[],"published":{"date-parts":[[2012,2,21]]}}}